MET-addicted non-small cell lung cancer (NSCLC) with high-level MET amplification and MET exon 14 alterations is known to be sensitive to treatment with crizotinib, while the presence of secondary MET mutations is described as a potential resistance mechanism [13,14]. The gene discussed is MET; the disease is non-small cell lung carcinoma.